Alpelisib (BYL719)

Catalog No.S2814

Alpelisib (BYL719) Chemical Structure

Molecular Weight(MW): 441.47

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Size Price Stock Quantity  
In DMSO USD 592 In stock
USD 370 In stock
USD 570 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • AN3CA (B), JHUEM2 (D), and MFE296 (H) cells were treated with the indicated doses of BGJ398 and BYL719 alone or in combination for 96 hours, and an SRB assay was subsequently performed.

    Mol Cancer Ther, 2017, 16(4):637-648. Alpelisib (BYL719) purchased from Selleck.

    BYL719 induces Apoptosis in MM cells. The effect of increasing concentrations of BYL719 (0-2.5 umol/l) for 48 h on the apoptosis of MM1s cells. The effect of BYL719 on the apoptosis signalling; cleaved PARP, caspase 3, caspase 9 by Western blotting. MM, multple myeloma.

    Br J Haematol 2014 165(1), 89-101. Alpelisib (BYL719) purchased from Selleck.

  • A549 cell was trypsinized and plated at 50% confluence in DMEM. 16 hours later, BYL719 was added at final concentrations of 0, 1, 5, 10 and 20uM. Another 24 hours later, cells were harvested in RIPA with protease and phosphatase inhibitor cocktail. Total protein concentration was measured by BCA method. Lysates equivalent to 20ug total protein were subject to Western Blot, using total- AKT, pS473-AKT, pT286-CyclinD1 and beta-actin (internal control) antibodies.

    Alpelisib (BYL719) purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.
Targets
PI3Kα [1]
(Cell-free assay)
5 nM
In vitro

BYL719 inhibits the proliferation of breast cancer cell lines harboring PIK3CA mutations, correlating with inhibition of various downstream signaling components of the PI3K/Akt pathway. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Detroit562 M1zwPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFuxUYQxNjFvMUCwJO69VQ>? M3nkXVczKGh? MUPJR|UxRTFwMUCg{txO MlLGNlU2PTB3NEm=
SNU-1076 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnHOnA1OC5zLUGwNEDPxE1? M3rPZVczKGh? Mn;kTWM2OD14LkiyJO69VQ>? NYXCepNuOjV3NUC1OFk>
SNU-1066 Mn;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XaO|AvOS1zMECg{txO NF\oVGE4OiCq NXzKOYdSUUN3ME2xMlE{KM7:TR?= MYGyOVU2ODV2OR?=
FaDu NXuxVoRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzHSXluOC5zLUGwNEDPxE1? NXz0VlFMPzJiaB?= NXjBV3BGUUN3ME2xPU43PiEQvF2= MXeyOVU2ODV2OR?=
SNU1041 MmXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXT2do06OC5zLUGwNEDPxE1? NWj2NGZ1PzJiaB?= M3;VW2lEPTB;MkCuOlUh|ryP MUeyOVU2ODV2OR?=
SCC25 MkPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MViwMlEuOTByIN88US=> MmPBO|IhcA>? MXXJR|UxRTR7LkOwJO69VQ>? M1\2XVI2PTVyNUS5
BON-1 M{XUTWZ2dmO2aX;uJGF{e2G7 MnjmNU8yOCEQvF2= NInqfGI1KGh? M1;6WIlvcGmkaYTzJHBKO0tiKFHLWEBU\XJ|MEipJIFv\CCvVF;SR|EwOiCjY4Tpeol1cWW| MoizNlUxOjZ{OUK=
QGP-1 NGXacXdHfW6ldHnvckBCe3OjeR?= MkiyNU8yOCEQvF2= MmnoOEBp NUnLe2lxcW6qaXLpeJMhWEl|SzCoRWtVKFOnckOwPEkh[W6mIH3UU3JEOS9{IHHjeIl3cXSrZYO= Mn\NNlUxOjZ{OUK=
MG-63 M2Cwc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETnVGZKSzVyPU[g{txO97zOIFnDPVA:OjRizszN NWnV[5lOOjR7NkG3PVA>
HOS MkPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3i5VGlEPTB;MUWg{txO97zOIFnDPVA:PDJizszN NH;iboMzPDl4MUe5NC=>
MOS-J MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLRUYhKSzVyPUGwJO69Ve,:jDDJR|kxRTN4IN88US=> NX[3UYpsOjR7NkG3PVA>
POS-1 NWW5clY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRThizszN89yNKEmFOUC9N|Yh|ryP MmnXNlQ6PjF5OUC=
92.1 M13B[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkW5OVAxNTJyMECgcm0> NVv6NYxmPSCm MnPTbY5pcWKrdIOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCDS2SgLHNmejR5MzmgeZAhfG9iMTFOwG0> NI\HXJkzPDV4M{W0NC=>
Mel270 NEWzPHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TOWFUxOC1{MECwJI5O NFn2fm42KGR? NIj0S5RqdmirYnn0d{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHLWEApW2W{NEezLUB2eCC2bzCxJO69VQ>? NWH0bmJKOjR3NkO1OFA>
Omm1.3 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILRRYI2ODBvMkCwNEBvVQ>? NX3Uem5oPSCm NGrabINqdmirYnn0d{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHLWEApW2W{NEezLUB2eCC2bzCxJO69VQ>? M3LvclI1PTZ|NUSw
Omm1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1r2XVUxOC1{MECwJI5O NGrCR2U2KGR? MULpcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGNVDCoV4VzPDd|KTD1dEB1dyBzIN88US=> MmjsNlQ2PjN3NEC=
C918 M{fNbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrSWVE2ODBvMkCwNEBvVQ>? M3P1OVUh\A>? NHLOfYFqdmirYnn0d{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHLWEApW2W{NEezLUB2eCC2bzCxJO69VQ>? NF7WR4szPDV4M{W0NC=>
Mel290 M1XSTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rmS|UxOC1{MECwJI5O NYDZ[lVqPSCm MoHLbY5pcWKrdIOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCDS2SgLHNmejR5MzmgeZAhfG9iMTFOwG0> M{fNbVI1PTZ|NUSw
OPM2 NIju[mZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUWwMlUuOi53IN88US=> MYq0PEBp NILFbIZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NHzQSJUzPDRyNUGyNS=>
OPM1 NEnUR3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPLdHNlOC53LUKuOUDPxE1? M{nUTlQ5KGh? NWrSdGNLcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M{LDelI1PDB3MUKx
U266 NELkcohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDNfo94OC53LUKuOUDPxE1? MUi0PEBp NETK[GlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Mn\DNlQ1ODVzMkG=
MM1R NIKzOoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV:wMlUuOi53IN88US=> NHzhNVA1QCCq MonkbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MVOyOFQxPTF{MR?=
MM1S MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NID5e4ExNjVvMj61JO69VQ>? M{HDRVQ5KGh? NUnCV3lFcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NGLQbYkzPDRyNUGyNS=>
H929 NHnL[I5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3flR|AvPS1{LkWg{txO MX60PEBp Mn\lbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NGC1d|QzPDRyNUGyNS=>
RPMI M3LCSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF[4bXoxNjVvMj61JO69VQ>? M1ziclQ5KGh? M3XweolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MVGyOFQxPTF{MR?=
SKBR3 NEf1SG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\vRlM{KM7:TR?= NF2yRYE2KGR? M4fybolvcGmkaYTzJFM297zHIHPlcIwh\3Kxd4To NVL4[5NLOjN7MUi3PVc>
MDA453 MmPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPCRm1nOzNizszN NGnPe4k2KGR? NF2wepVqdmirYnn0d{A{QO,:hTDj[YxtKGe{b4f0bC=> M17lPVI{QTF6N{m3
EFM192A MoDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTuN|Mh|ryP NXzFeJBUPSCm Mn;3bY5pcWKrdIOgNlfwxIViY3XscEBoem:5dHi= MmfwNlM6OTh5OUe=
AU565 MnfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PRUVM{KM7:TR?= MV21JIQ> NVP3eph4cW6qaXLpeJMhOjcxvJWgZ4VtdCCpcn;3eIg> MVqyN|kyQDd7Nx?=
MDA361 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrLN|k{OyEQvF2= MYC1JIQ> NFK4cpJqdmirYnn0d{A1PO,:hTDj[YxtKGe{b4f0bC=> MmLoNlM6OTh5OUe=
BT474 NV\WXnhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzDbWs{OyEQvF2= NX;Eb2J6PSCm M3TRbolvcGmkaYTzJFE397zHIHPlcIwh\3Kxd4To NGfseoEzOzlzOEe5Oy=>
HCC202 NF3nUXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjiXYx2OzNizszN MXu1JIQ> Ml7FbY5pcWKrdIOgNlDwxIViY3XscEBoem:5dHi= MkTtNlM6OTh5OUe=
KPL4 MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnmN|Mh|ryP M33INFUh\A>? NFfBO4pqdmirYnn0d{A2QO,:hTDj[YxtKGe{b4f0bC=> NUHSb3dFOjN7MUi3PVc>
NCL-N87 MmLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnv5N|Mh|ryP MX:1JIQ> NXPn[|N3cW6qaXLpeJMhOzIxvJWgZ4VtdCCpcn;3eIg> NE[zZ2ozOzlzOEe5Oy=>
UACC812 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jINFM{KM7:TR?= NVz6eIk4PSCm NUXFbotqcW6qaXLpeJMhOjgxvJWgZ4VtdCCpcn;3eIg> NFmzOIYzOzlzOEe5Oy=>
HCC2218 NUnpcmxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDjbpk{OyEQvF2= MUC1JIQ> NUjkcHRncW6qaXLpeJMhOTYxvJWgZ4VtdCCpcn;3eIg> Mli3NlM6OTh5OUe=
HCC1569 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonnN|Mh|ryP NIP6Wo42KGR? NIeyfHNqdmirYnn0d{A297zHIHPlcIwh\3Kxd4To M2n3d|I{QTF6N{m3
OE19 M1PSbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWSzN{DPxE1? NHPPZVY2KGR? MXHpcohq[mm2czCyN-+9jSClZXzsJIdzd3e2aB?= NYjQRmVyOjN7MUi3PVc>
OE33 NF\CW|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWOzN{DPxE1? M{nXW|Uh\A>? M1X4UYlvcGmkaYTzJFI{97zHIHPlcIwh\3Kxd4To MU[yN|kyQDd7Nx?=
JIMT1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUO4NI9yOzNizszN MU[1JIQ> MYrpcohq[mm2czC589yGKGOnbHyg[5Jwf3Sq MWiyN|kyQDd7Nx?=
HCC1954 Mlm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmj1N|Mh|ryP NU\HU2U3PSCm NIHSVVhqdmirYnn0d{AzQe,:hTDj[YxtKGe{b4f0bC=> MmfoNlM6OTh5OUe=
NUGC4 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PVN|M{KM7:TR?= M2[0eVUh\A>? MWLpcohq[mm2czCxOQ+9jSClZXzsJIdzd3e2aB?= NVPmcFMyOjN7MUi3PVc>
ZR-75-30 NXiyNVJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWmzN{DPxE1? NILpclE2KGR? MkTPbY5pcWKrdIOgMVE297zHIHPlcIwh\3Kxd4To NXrwbHAyOjN7MUi3PVc>

... Click to View More Cell Line Experimental Data

In vivo BYL719(>270 mg/d) shows statistically significant dose-dependent anti-tumor efficacy in PIK3CA mutant xenograft models in rodents. BYL719 has a low clearance, a half-life of 8.5 h and its exposure increases dose proportionally between 30mg/d and 450mg/d, displaying a low inter-individual variability in Cmax and AUC in human. BYL719(270mg/d) shows first signs of clinical efficacy include 1 confirmed partial response in a patient with ER+ breast cancer, and significant PET responses (PMR) and/or tumor shrinkage are achieved in 8 out of 17 evaluated patients. [1]

Protocol

Solubility (25°C)

In vitro DMSO 88 mg/mL (199.33 mM)
Ethanol 2 mg/mL (4.53 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 441.47
Formula

C19H22F3N5O2S

CAS No. 1217486-61-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01872260 Recruiting Breast Cancer Novartis Pharmaceuticals|Novartis October 22, 2013 Phase 1
NCT02624557 Recruiting Hepatic Impairment Novartis Pharmaceuticals|Novartis December 21, 2015 Phase 1
NCT02145312 Not yet recruiting Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck Yonsei University October 2016 Phase 2
NCT02298595 Not yet recruiting Carcinoma, Squamous|Squamous Cell Carcinoma|Oropharyngeal Neoplasms|Oropharyngeal Cancer Julie E. Bauman, MD, MPH|Novartis|University of Pittsburgh August 2016 Phase 1|Phase 2
NCT02550743 Recruiting Rectal Cancer howard safran|Brown University|Lifespan|Novartis Pharmaceuticals Corporation (Financial supporter) June 2016 Phase 1
NCT02734615 Recruiting Advanced or Metastatic ER+ Breast Cancer Novartis Pharmaceuticals|Novartis June 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy Alpelisib (BYL719) | Alpelisib (BYL719) supplier | purchase Alpelisib (BYL719) | Alpelisib (BYL719) cost | Alpelisib (BYL719) manufacturer | order Alpelisib (BYL719) | Alpelisib (BYL719) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID